// December 11, 2025
Different medicines, same chokepoints: Key starting materials concentrate supply chain risk for widely used therapeutic classes
USP’s ongoing series on geographic concentration in U.S.
// October 14, 2025
Concentrated origins, widespread risk: New USP insights on key starting materials
This blog is part of a series on the geographic concentration of pharmaceutical manufacturing
// July 28, 2025
India and the EU dominate API manufacturing for the most-used ATC-3 therapeutic classes in the U.S. market
This blog continues our exploration of global pharmaceutical supply chain vulnerabilities, specif
// April 17, 2025
Over half of the active pharmaceutical ingredients (API) for prescription medicines in the U.S. come from India and the European Union
This blog is part of a series on the geographic concentration of pharmaceutical manufacturing
